![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » ADHEREX BEGINS TRIAL OF ADH-1 PLUS CHEMOTHERAPY
ADHEREX BEGINS TRIAL OF ADH-1 PLUS CHEMOTHERAPY
October 4, 2006
Adherex Technologies has started a Phase I trial of ADH-1 in combination with chemotherapy in conjunction with the U.S. Oncology Research network. The trial will be offered at 10 sites in the network's innovative Translational Oncology Phase I Research Program.
This Phase I dose-escalation study is intended to define the dose-limiting toxicities and maximum-tolerated dose of ADH-1 in three separate combinations (in effect, three separate sub-studies): ADH-1 plus docetaxel (Taxotere), ADH-1 plus carboplatin, and ADH-1 plus capecitabine (Xeloda). Docetaxel is currently used in the treatment of breast cancer, prostate cancer and non-small-cell lung cancer, among others. Carboplatin is commonly used in the treatment of ovarian and lung cancer. Capecitabine is currently used to treat breast and colon cancer. Preliminary evidence of anti-tumor activity will also be monitored. The company expects to enroll an aggregate of up to 55 patients with N-cadherin-positive solid tumors into the three arms of the trial.
Adherex's clinical development program for ADH-1 also includes an ongoing single-agent Phase II trial, which is evaluating the anti-tumor activity and tolerability of repeated doses of ADH-1 at six sites in Canada and three sites in the U.S. That study, which is anticipated to conclude patient enrollment by the end of 2006, is studying ADH-1 in patients with lung, esophageal, adrenocortical, kidney and liver cancers whose tumors express the molecular target N-cadherin. The company is also conducting a Phase II single-agent study of ADH-1 in Europe, which is enrolling patients with N-cadherin-positive ovarian or lung cancer and is also expected to complete patient enrollment by the end of 2006. Adherex also has plans to conduct a clinical study of ADH-1 in combination with melphalan for the treatment of melanoma, with the trial expected to begin later this year.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct